Pharma Holdings
Develops intranasal antimicrobial drugs for patients with respiratory viral infections
Highlights
- New on EvolcAdded 2026-10-29
About Pharma Holdings
Pharma Holdings develops intranasal virucidal products intended to target early respiratory viral infections and reduce the risk of severe complications. Its lead nasal spray uses antimicrobial peptides.
The company is a privately owned clinical-stage pharmaceutical company. It uses contract research and manufacturing organizations and external advisors rather than operating its own laboratories or research facilities.
Pharma Holdings has offices in Oslo and Tromsø, Norway. The company was founded in 2017 as a spin-off from research by Lytix Biopharma; registry records give its founding date as 2016-10-25.
Product: Intranasal antimicrobial peptide products intended to treat early respiratory viral infections.
Jobs at Pharma Holdings
Leadership
- Christian Lütken · CEO, Chief Executive OfficerSource: company website
- Torsteinn Erlingsson · CFO, Chief Financial OfficerSource: company website
More biotech & pharma companies
Pluvia
Develops small-molecule drugs for patients with rare protein-misfolding disorders, starting with phenylketonuria (PKU)New on EvolcPreviwo
Probiotic products for farmed salmon and trout that strengthen fish health in aquacultureNew on EvolcProphylaxia
Researches salmon signalling substances such as SNAP as a sea lice alternative for salmon farmingNew on EvolcQuantidoc
Immune barrier health monitoring for fish farms and hatcheries using its VERIBARR™ analyses of gills, skin and gutNew on EvolcRegenics
Develops marine-derived wound care products for treating burns and chronic woundsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- WooCommerce
- WordPress
- jQuery
- nginx